Physician profile
Nathan B Chase
NPI 1174533491
$691.38
in general payments reported to CMS, 2019-2025
16 companies · $41.96 in 2025
The $41.96 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $47.70 · 2022: $39.47 · 2023: $57.02 · 2024: $15.07 · 2025: $41.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $73.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $67.47 | 2019-2024 | Shingrix |
| Abbott Laboratories | $66.33 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $65.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $60.97 | 2019 | |
| Astellas Pharma US INC | $51.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.03 | 2019-2020 | |
| Pfizer INC. | $32.62 | 2019-2023 | |
| Amgen INC. | $30.95 | 2019-2025 | Evenity |
| Lundbeck LLC | $20.62 | 2023 | Rexulti |
| Seqirus USA INC | $16.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.49 | 2019 | |
| Abbvie INC. | $13.93 | 2019 | |
| Merck Sharp & Dohme LLC | $11.35 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.